Author(s) :

Dr. Prashant M. Tayade, Mr. Abhay Shripad Joshi.

Volume/Issue :

Abstract :

In India, pharmacovigilance practices have been gradually evolving over the past decade in order to better monitor drug safety metrics. The traditional system of spontaneously reporting adverse drug reactions (ADRs) to regulatory authorities is no longer feasible, given the large number of drugs and patients in India. There is still a need for better coordination between different stakeholders, and for more resources to be allocated to such activities. This article looks at some of the most recent developments in this area, as well as their implications for patient outcomes. The Pharmacovigilance Programme of India (PvPI) was established in 2010 and is managed by the Central Drug Standard Control Organization (CDSCO). The PvPI monitors the safety of medicines that are marketed in India, with the aim of protecting patients from adverse effects. It collects data on adverse events through a reporting system accessible to both health care professionals and members of the public. The National Pharmacovigilance Monitoring Centre (NADRMC) in India monitors adverse drug reactions (ADRs) from all over the country. The centre collects data from various sources such as hospitals, clinics, voluntary reporting by patients/caregivers and health care professionals. This will help reduce healthcare costs as well as protect patient safety by minimizing risk of harm associated with inappropriate use of drugs.

No. of Downloads :

8